Abstract
The effectiveness of combinations of rifabutin with atovaquone, clindamycin, pyrimethamine, or sulfadiazine in the treatment of toxoplasmic encephalitis in a murine model was investigated. Doses of each drug that were not effective in reducing inflammation in the brain of mice with toxoplasmic encephalitis when used alone were used in combination with a dose of rifabutin which was minimally effective. At the end of each period of therapy (15 or 30 days), brains of mice were examined histopathologically and the severity of the inflammatory lesions scored. Treatment with rifabutin in combination with pyrimethamine or sulfadiazine did not reduce brain inflammation significantly when compared to treatment with each drug alone. In contrast, treatment with rifabutin plus atovaquone for 15 or 30 days or with rifabutin plus clindamycin for 15 days resulted in statistically significant reduction in the inflammation. These results suggest that combining rifabutin with certain drugs that are active againstToxoplasma gondii may be useful for the treatment of toxoplasmic encephalitis in humans and may allow for a reduction in dosage of either or both drugs with a resulting reduction in untoward side effects.
Similar content being viewed by others
References
Wong SY, Remington JS: Biology ofToxoplasma gondii. AIDS 1993, 7:299–316.
Luft BJ, Remington JS: Toxoplasmic encephalitis in AIDS. Clinical Infectious Diseases 1992, 15: 211–222.
Israelski DM, Remington JS: Toxoplasmic encephalitis in patients with AIDS. Infectious Disease Clinics of North America 1988, 2: 429–445.
Wong SY, Remington JS: Toxoplasmosis in the setting of AIDS. In: Broder S, Merigan TC, Bolognesi D (ed): Textbook of AIDS medicine. Williams and Wilkins, Baltimore, 1994, p. 223–257.
Wong SY, Israelski DM, Remington JS: AIDS associated toxoplasmosis. In: Sande MA, Volberding P (ed): The medical management of AIDS. W.B. Saunders, Philadelphia, 1995, p. 460–493.
Araujo FG, Remington JS: Recent advances in the search for new drugs for treatment of toxoplasmosis. International Journal of Antimicrobial Agents 1992, 1: 153–164.
Araujo FG, Slifer T, Remington JS: Rifabutin is active in models of murine toxoplasmosis. Antimicrobial Agents and Chemotherapy 1994, 38: 570–575.
Araujo FG, Huskinson-Mark J, Gutteridge WE, Remington JS: In vitro and in vivo activities of the hydroxynaphthoquinone 566C80 against the cyst form ofToxoplasma gondii. Antimicrobial Agents and Chemotherapy 1992, 36: 326–330.
Israelski DM, Araujo FG, Conley FK, Suzuki Y, Remington JS: Treatment with anti-L3T4 (CD4) monoclonal antibody reduces the inflammatory response in toxoplasmic encephalitis. Journal of Immunology 1989, 142: 954–958.
O'Brien RJ, Lyle MA, Snider DEJ: Rifabutin (ansamycin LM427): a new rifamycin-S derivative for the treatment of mycobacterial diseases. Reviews of Infectious Diseases 1987, 9: 519–530.
Gutteridge WE: New antiprotozoal agents. International Journal of Parasitology 1987, 17: 121–130.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Araujo, F.G., Suzuki, Y. & Remington, J.S. Use of rifabutin in combination with atovaquone, clindamycin, pyrimethamine, or sulfadiazine for treatment of toxoplasmic encephalitis in mice. Eur. J. Clin. Microbiol. Infect. Dis. 15, 394–397 (1996). https://doi.org/10.1007/BF01690096
Issue Date:
DOI: https://doi.org/10.1007/BF01690096